Asensus Surgical Closes Merger with KARL STORZ

Asensus Surgical announced the closing of the merger with KARL STORZ, following approval by the Asensus stockholders.
 
KARL STORZ Endoscopy-America acquired all outstanding shares of Asensus for $0.35 per share in cash. The company has become a subsidiary of KARL STORZ and its stock is no longer trading on the NYSE American Exchange.
 
KARL STORZ said it identified Asensus for acquisition due to the organization’s talent and technology. It was deemed a perfect fit because of a similar philosophy and vision, as well as experience bringing its first-generation Senhance surgical robot to market. Its second-gen LUNA system is also positioned to provide more robotic precision, dexterity, and range of motion manipulation. This complements KARL STORZ’s capabilities in advanced visualization.
 
LUNA is currently under development and hasn’t yet been submitted to or cleared by the FDA or other global regulators. It’s not for sale yet in any market.
 
“We are thrilled to complete this merger with KARL STORZ, which marks an exciting new chapter for Asensus,” said Anthony Fernando, Asensus Surgical president and CEO. “By joining forces with a leading company in endoscopy that became a system provider for integrated MedTech, we are well-positioned to accelerate the development and delivery of our innovative robotic and digital surgical solutions. This union will benefit patients and surgeons worldwide by advancing precise, safer, and more predictable surgical outcomes.”
 
“Asensus’ cutting-edge technology and expertise in robotic surgery complements our comprehensive portfolio of surgical solutions,” added Karl-Christian Storz, CEO of KARL STORZ. “This enhances our portfolio and market presence, strengthening our position in the growing robotic and digital surgical market, particularly with the development of the next generation LUNA™ system. We are thrilled to welcome 200-plus talented Asensus team members into our company. Together, we will revolutionize healthcare by delivering better outcomes for patients and surgical teams worldwide.”